Imprimis Pharmaceuticals Prices 1.84M Share Offering at $5.25/Share

Imprimis Pharmaceuticals

, today announced the pricing of an underwritten public offering of 1,840,000 shares of its common stock at a price to the public of $5.25 per share, for gross proceeds of approximately $9.66 million. The net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $8.13 million. Subject to customary conditions, Imprimis expects to close the sale of its common stock on or about February 13, 2013. In connection with the offering Imprimis completed a 1-for-5 reverse stock split on February 7, 2013.  Beginning on February 8, 2013, Imprimis Pharmaceuticals, Inc. common shares will trade on The NASDAQ Capital Market under the ticker symbol IMMY.   MDB Capital Group, LLC is the sole book-running manager of the offering and Aegis Capital Corp. is acting as co-manager. Imprimis has granted the underwriters a 45-day option to purchase up to an additional 276,000 shares of Imprimis' common stock to cover over-allotments, if any. This announcement shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer